Turing Pharmaceuticals, the drug company that jacked up the price of a drug used by AIDS and cancer patients by more than 5,000%, is facing an antitrust probe by New York Attorney General Eric Schneiderman.
The drug company raised the price of Daraprim, a 62-year old drug no longer under patent protection, to $750 a tablet from $13.50.
The drug’s main use is to treat life-threatening parasitic infections but it is also needed by some infants and patients with AIDS. The price hike sparked howls of protest and the company promised to lower the price but has yet to do so.
The investigation, which was confirmed by Schneiderman’s office, is looking at whether Turing is restricting the distribution of Daraprim to thwart generic competition that would prevent it from maintaining the massive price increase. The office is concerned Turing restricted distribution of the drug specifically so generic drug manufacturers couldn’t get the samples they need to create their own version.
Full content: Human Rights Campaign
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI